Gynecologic Cancers

Latest News

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.
The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

September 15th 2025

Findings from a phase 1 and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

September 10th 2025

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.
Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

September 4th 2025

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

September 4th 2025

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

July 25th 2025

Latest CME Events & Activities

More News